2016
Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysis
Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysis. Alimentary Pharmacology & Therapeutics 2016, 44: 1090-1101. PMID: 27640785, DOI: 10.1111/apt.13798.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsBenzimidazolesCarcinoma, HepatocellularCost-Benefit AnalysisDisease ProgressionDrug Therapy, CombinationFluorenesGenotypeHepacivirusHepatitis CHumansLiver CirrhosisLiver NeoplasmsLiver TransplantationNeoplasm Recurrence, LocalQuality-Adjusted Life YearsRibavirinSofosbuvirUnited StatesConceptsHepatitis C virusLiver transplantationTime of transplantHCV recurrencePost-LTCost-effective strategyTreatment of HCVEnd-stage liver disease (MELD) scoreOptimal timingDonor LT recipientsLiver Disease scoreHCV genotype 1Hepatitis C therapyMarkov state transition modelHepatocellular carcinoma casesBase-case analysisSeparate treatment strategiesCost-effectiveness analysisAllograft failureDecompensated diseaseOngoing viraemiaPre-LTHCV treatmentLT recipientsMELD score
2014
Prognosis of Patients With Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
Njei B, Konjeti VR, Ditah I. Prognosis of Patients With Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Gastrointestinal Cancer Research : GCR 2014, 7: 49-54. PMID: 24799971, PMCID: PMC4007676.Peer-Reviewed Original ResearchMean overall survivalOverall survivalFL-HCCHepatocellular carcinomaNoncirrhotic patientsSystematic reviewConventional HCCPrognosis of patientsConventional hepatocellular carcinomaFibrolamellar hepatocellular carcinomaRandom-effects modelOutcomes of interestSignificant increaseTypes of HCCLiver transplantationFibrolamellar variantHepatic resectionBetter prognosisClinical courseSurvival outcomesTherapeutic optionsCochrane LibrarySubgroup analysisEgger's testRevMan 5.1
2013
Persistent racial disparities in survival among u.s. Adults with hepatocellular carcinoma after liver transplantation: the paradox of all-cause and cause-specific mortality.
Njei B, Ditah I, Lim JK. Persistent racial disparities in survival among u.s. Adults with hepatocellular carcinoma after liver transplantation: the paradox of all-cause and cause-specific mortality. Gastrointestinal Cancer Research : GCR 2013, 6: 73-4. PMID: 23936546, PMCID: PMC3737508.Peer-Reviewed Original Research